Laboratory of Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
Front Immunol. 2024 Apr 23;15:1387011. doi: 10.3389/fimmu.2024.1387011. eCollection 2024.
An unbiased screening of which proteins are deregulated in vitiligo using proteomics can offer an enormous value. It could not only reveal robust biomarkers for detecting disease activity but can also identify which patients are most likely to respond to treatments. We performed a scoping review searching for all articles using proteomics in vitiligo. Eight manuscripts could be identified. Unfortunately, very limited overlap was found in the differentially expressed proteins between studies (15 out of 272; 5,51%) with variable degrees of the type of proteins and a substantial variety in the prevalence of acute phase proteins (range: 6-65%). Proteomics research has therefore brought little corroborating evidence on which proteins are differentially regulated between vitiligo patients and healthy controls or between active and stable vitiligo patients. While a limited patient size is an obvious weakness for several studies, an incomplete description of patient characteristics is an unfortunate and avoidable shortcoming. Additionally, the variations in the used methodology and analyses may further contribute to the overall observed variability. Nonetheless, more recent studies investigating the response to treatment seem to be more robust, as more differentially expressed proteins that have previously been confirmed to be involved in vitiligo were found. The further inclusion of proteomics analyses in clinical trials is recommended to increase insights into the pathogenic mechanisms in vitiligo and identify reliable biomarkers or promising drug targets. A harmonization in the study design, reporting and proteomics methodology could vastly improve the value of vitiligo proteomics research.
使用蛋白质组学对白癜风中失调蛋白进行无偏筛选具有重要价值。它不仅可以揭示用于检测疾病活动的稳健生物标志物，还可以确定哪些患者最有可能对治疗产生反应。我们进行了一项范围界定审查，搜索了所有使用蛋白质组学研究白癜风的文章。确定了 8 篇论文。不幸的是，研究之间差异表达蛋白之间的重叠非常有限（272 个中有 15 个，占 5.51%），而且蛋白类型和急性期蛋白的流行程度存在差异（范围：6-65%）。因此，蛋白质组学研究几乎没有提供关于白癜风患者与健康对照组之间或活动期与稳定期白癜风患者之间差异调节蛋白的证据。尽管几个研究的患者样本量小是一个明显的弱点，但对患者特征的描述不完整是一个不幸且可以避免的缺陷。此外，所使用的方法和分析的变化也可能导致总体观察到的变异性。尽管如此，最近研究治疗反应的研究似乎更稳健，因为发现了更多以前证实与白癜风有关的差异表达蛋白。建议将蛋白质组学分析纳入临床试验，以增加对白癜风发病机制的了解，并确定可靠的生物标志物或有前途的药物靶点。研究设计、报告和蛋白质组学方法的协调一致可以大大提高白癜风蛋白质组学研究的价值。
